Tailored management of cavernous malformations in women: considerations and strategies—a review
Open Access
- 24 October 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 15, 1487808
Abstract
Purpose of review: Cavernous malformations (CM) are vascular lesions in the brain and spinal cord, characterized by clusters of endothelial-lined caverns lacking proper tight junctions. These malformations may be discovered incidentally or present with symptoms such as headaches, focal neurologic deficits, or seizures, with or without hemorrhage. This review focuses on non-surgical management considerations important for women with CM, who face challenges related to pregnancy, exogenous hormone use, anticonvulsive therapy, bone health, and mental health.Recent findings: Emerging evidence suggests that both estrogen and progesterone may influence CM lesion behavior. Exogenous hormones, including those in oral contraceptives and oral hormone replacement therapy, indicate an elevated risk of symptomatic hemorrhage (SH) and may also influence seizure frequency and severity, particularly in women taking antiseizure medications (ASMs). Data suggest that the risk of CM hemorrhage during pregnancy is similar to the risk when not pregnant, although limitations to these studies will be reviewed.Summary: This review synthesizes the current literature on the interplay between estrogen and progesterone and CM lesion behavior, highlighting the importance of gender- and sex-specific factors in clinical decision-making. Special attention is given to the implications of exogenous hormone use, seizure management, and the psychological well-being of women with CM, underscoring the need for a multidisciplinary approach tailored to the unique needs of this patient population.Keywords
Funding Information
- UCB
This publication has 86 references indexed in Scilit:
- A Review of Concordance and Quality in Clinical Guidelines for Hormonal Contraceptives to Mitigate Drug–Drug Interactions in Women With EpilepsyPharmacoepidemiology and Drug Safety, 2024
- Incidence, Prevalence, and Clinical Presentation of Cerebral Cavernous Malformations2020
- Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After PregnancyClinical Pharmacokinetics, 2020
- Affected health domains in patients with brainstem cavernous malformationsActa Neurochirurgica, 2019
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Non-Sponsored Symposia AbstractsOsteoporosis International, 2018
- Population-Based Prevalence of Cerebral Cavernous Malformations in Older AdultsJAMA Neurology, 2017
- Breastfeeding in Children of Women Taking Antiepileptic DrugsJAMA Pediatrics, 2014
- Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through BreastfeedingJAMA Neurology, 2013
- Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complexHuman Mutation, 2008
- Amniocentesis or chorionic villus sampling for prenatal genetic testing: A decision analysisJournal of Clinical Epidemiology, 1991